- Article
Immunological and Safety Considerations When Selecting the Dose Formulation of a Purified Inactivated Zika Virus Vaccine (PIZV)
- Camilo J. Acosta,
- Francesco Nordio,
- Eloi Kpamegan,
- Kelley J. Moss,
- Pradeep Kumar and
- Kazuhiro Hirata
We previously reported the first-in-human assessment of three doses (2, 5, and 10 µg) of purified inactivated Zika virus vaccine (PIZV or TAK-426) in the Phase 1 ZIK-101 study (NCT03343626). Here, we report dose selection based on extended safe...